IBI-3031 Sales Forecast, and Market Size Analysis - 2034

Key Factors Driving IBI-3031 Growth

• First-in-Class Bispecific Mechanism Targeting Two Key TED Pathways

IBI-3031 simultaneously targets the insulin-like growth factor-1 receptor (IGF-1R) and the thyroid-stimulating hormone receptor (TSHR), the two receptors that play central roles in TED pathogenesis. Activation of the IGF-1R/TSHR signaling complex drives orbital fibroblast activation, inflammation, adipogenesis, and tissue remodeling. By inhibiting both pathways, IBI-3031 has the potential to deliver broader disease control than therapies targeting IGF-1R alone, while also potentially modulating thyroid function. This differentiated mechanism provides a strong scientific rationale and commercial differentiation if clinical efficacy is confirmed.

• Significant Unmet Need Despite Availability of Existing Therapy

TED remains a rare but debilitating autoimmune disease, with many patients experiencing persistent proptosis, diplopia, pain, and vision impairment. Although IGF-1R inhibition has been clinically validated, treatment options remain limited, particularly outside the United States, and there is continued demand for therapies with improved efficacy, durability, convenience, and global accessibility. A successful bispecific antibody addressing both IGF-1R and TSHR could capture patients who have inadequate responses or limited access to current therapies. Peer-reviewed studies continue to identify the IGF-1R/TSHR signaling complex as a major therapeutic target in TED.

• Advancement into First-in-Human Clinical Development

A major catalyst for IBI-3031 is its transition into clinical testing. According to ClinicalTrials.gov, Innovent initiated a Phase I randomized, double-masked, placebo-controlled, dose-escalation study in TED, evaluating both intravenous and subcutaneous administration. The study plans to enroll approximately 66 participants and will assess safety, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy. Successful completion of this study would substantially de-risk the asset and support progression into Phase II development.

• Potential for Convenient Subcutaneous Administration

Unlike currently approved intravenous biologics, IBI-3031 is being evaluated in both subcutaneous (SC) and intravenous (IV) formulations during Phase I. If the SC formulation demonstrates comparable efficacy and pharmacokinetics, it could improve patient convenience, reduce infusion-center dependence, lower healthcare resource utilization, and enhance market adoption. Convenient dosing has become an increasingly important competitive factor for biologic therapies in autoimmune diseases.

• Strong Development and Commercialization Capabilities of Innovent Biologics

Innovent has established extensive experience in developing and commercializing monoclonal antibodies and biologics in China across oncology, immunology, ophthalmology, and metabolic diseases. Its integrated manufacturing capabilities, regulatory expertise, and commercialization infrastructure increase the probability of efficient clinical development and eventual market launch if IBI-3031 demonstrates positive efficacy and safety. These capabilities also enhance the potential for future regional or global partnerships supporting broader commercialization.

IBI-3031 Recent Developments

In May 2026, Innovent Biologics, Inc. announced that it will present multiple clinical and preclinical data from IBI3002(IL-4Rα/TSLP), IBI3038(IGF-1R/IL-6), IBI3031(IGF-1R/TSHR) at the 2026 American Thoracic Society (ATS) International Conference, held in Orlando, Florida (US) and the 2026 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, held in Denver, Colorado (US).

“IBI-3031 Sales Forecast, and Market Size Analysis - 2034” report provides comprehensive insights of IBI-3031 for potential indication like Graves ophthalmopathy in the 7MM. A detailed picture of IBI-3031’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the IBI-3031 for potential indications. The IBI-3031 market report provides insights about IBI-3031’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current IBI-3031 performance, future market assessments inclusive of the IBI-3031 market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of IBI-3031 sales forecasts, along with factors driving its market.

IBI-3031 Drug Summary

IBI-3031 is an investigational bispecific monoclonal antibody developed by Innovent Biologics for the treatment of thyroid eye disease (TED). The antibody is designed to simultaneously target the insulin-like growth factor-1 receptor (IGF-1R) and the thyroid-stimulating hormone receptor (TSHR), two key drivers of TED pathogenesis. By dual inhibition of these receptors, IBI-3031 is intended to reduce autoimmune signaling, orbital inflammation, tissue remodeling, and thyroid dysfunction, potentially providing synergistic therapeutic benefits beyond single-target approaches. The drug is being evaluated for administration via subcutaneous or intravenous injection, with flexibility to support both single- and multiple-dose regimens. As of 2026, IBI-3031 is undergoing a Phase I randomized, double-masked, placebo-controlled, first-in-human dose-escalation study in patients with thyroid eye disease to assess its safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy. The therapy remains investigational and has not yet received regulatory approval. The report provides IBI-3031’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the IBI-3031 Market Report

The report provides insights into:

• A comprehensive product overview including the IBI-3031 MoA, description, dosage and administration, research and development activities in potential indication like Graves ophthalmopathy.
• Elaborated details on IBI-3031 regulatory milestones and other development activities have been provided in IBI-3031 market report.
• The report also highlights IBI-3031‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The IBI-3031 market report also covers the patents information, generic entry and impact on cost cut.
• The IBI-3031 market report contains current and forecasted IBI-3031 sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The IBI-3031 market report also features the SWOT analysis with analyst views for IBI-3031 in potential indications.

Methodology

The IBI-3031 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

IBI-3031 Analytical Perspective

• In-depth IBI-3031 Market Assessment

This IBI-3031 sales market forecast report provides a detailed market assessment of IBI-3031 for potential indication like Graves ophthalmopathy in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted IBI-3031 sales data uptil 2034.

• IBI-3031 Clinical Assessment

The IBI-3031 market report provides the clinical trials information of IBI-3031 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

IBI-3031 Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

IBI-3031 Market Potential & Revenue Forecast

• Projected market size for the IBI-3031 and its key indications
• Estimated IBI-3031 sales potential (IBI-3031 peak sales forecasts)
• IBI-3031 Pricing strategies and reimbursement landscape

IBI-3031 Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• IBI-3031 Market positioning compared to existing treatments
• IBI-3031 Strengths & weaknesses relative to competitors

IBI-3031 Regulatory & Commercial Milestones

• IBI-3031 Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

IBI-3031 Clinical Differentiation

• IBI-3031 Efficacy & safety advantages over existing drugs
• IBI-3031 Unique selling points

IBI-3031 Market Report Highlights

• In the coming years, the IBI-3031 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The IBI-3031 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence IBI-3031’s dominance.
• Other emerging products for Graves ophthalmopathy are expected to give tough market competition to IBI-3031 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of IBI-3031 in potential indications.
• Analyse IBI-3031 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted IBI-3031 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of IBI-3031 in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of IBI-3031? How strong is IBI-3031’s clinical and commercial performance?
• What is IBI-3031’s clinical trial status in each individual indications such as Graves ophthalmopathy and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the IBI-3031 Manufacturers?
• What are the key designations that have been granted to IBI-3031 for potential indications? How are they going to impact IBI-3031’s penetration in various geographies?
• What is the current and forecasted IBI-3031 market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of IBI-3031 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to IBI-3031 for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is IBI-3031? What is the duration of therapy and what are the geographical variations in cost per patient?

This product will be delivered within 2 business days.